Asterand, a provider of human tissue and human-tissue based services, has entered a global research agreement with Lundbeck, which develops drugs for central nervous-system disorders.
This agreement will allow scientists at Lundbeck's global research locations to access Asterand's Xpressbank of human tissue and clinical data and the Phasezero drug-discovery services platform to advance development of treatments for psychiatric and neurological disorders.
Lundbeck will use the services to help find treatments for diseases such as Alzheimer's, Parkinson's and schizophrenia.
